Molecular therapy for obesity and diabetes based on a long-term increase in hepatic fatty-acid oxidation by Orellana Gavaldà, Josep Maria et al.
Molecular Therapy for Obesity and Diabetes Based on
a Long-Term Increase in Hepatic Fatty-Acid Oxidation
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Obesity-induced insulin resistance is associated with both ectopic lipid deposition and
chronic, low-grade adipose tissue inflammation. Despite their excess fat, obese individuals
show lower fatty-acid oxidation (FAO) rates. This has raised the question of whether burn-
ing off the excess fat could improve the obese metabolic phenotype. Here we used human-
safe nonimmunoreactive adeno-associated viruses (AAV) to mediate long-term hepatic
gene transfer of carnitine palmitoyltransferase 1A (CPT1A), the key enzyme in fatty-acid
b-oxidation, or its permanently active mutant form CPT1AM, to high-fat diet-treated and
genetically obese mice. High-fat diet CPT1A- and, to a greater extent, CPT1AM-expressing
mice showed an enhanced hepatic FAO which resulted in increased production of CO2,
adenosine triphosphate, and ketone bodies. Notably, the increase in hepatic FAO not only
reduced liver triacylglyceride content, inflammation, and reactive oxygen species levels but
also systemically affected a decrease in epididymal adipose tissue weight and inflammation
and improved insulin signaling in liver, adipose tissue, and muscle. Obesity-induced
weight gain, increase in fasting blood glucose and insulin levels, and augmented expression
of gluconeogenic genes were restored to normal only 3 months after AAV treatment. Thus,
CPT1A- and, to a greater extent, CPT1AM-expressing mice were protected against obe-
sity-induced weight gain, hepatic steatosis, diabetes, and obesity-induced insulin resist-
ance. In addition, genetically obese db/db mice that expressed CPT1AM showed reduced
glucose and insulin levels and liver steatosis. Conclusion: A chronic increase in liver FAO
improves the obese metabolic phenotype, which indicates that AAV-mediated CPT1A
expression could be a potential molecular therapy for obesity and diabetes. (HEPATOLOGY
2010;000:000-000.)
O
besity is a major risk factor for disorders rang-
ing from insulin resistance and type 2 diabetes
(T2D) to hepatic steatosis and cardiovascular
disease. The incidence of obesity is increasing worldwide
and a concerted effort is being made to understand its
pathogenesis. Two main mechanisms have been pro-
posed to explain obesity-induced insulin resistance: on
the one hand the ectopic deposition of triacylglyceride
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(TAG) outside the adipose tissue,1 and on the other, the
heightened inflammatory state of the adipose tissue and
liver.2
However, the ultimate cause of obesity is an energy
imbalance between intake and expenditure, leading to
the accumulation of excess nutrients in lipid deposits.
Therefore, any strategy able to tilt the balance towards
fatty-acid oxidation (FAO) could improve obesity-
induced disorders. Malonyl-CoA, derived from glucose
metabolism and the first intermediate in lipogenesis,
regulates FAO by inhibiting carnitine palmitoyltrans-
ferase 1 (CPT1). This makes CPT1 the rate-limiting
step in mitochondrial fatty-acid b-oxidation. Short-
term genetic studies that increased FAO in liver
showed a decrease in hepatic TAG content3 and insu-
lin resistance in obese rodents.4,5 However, to date
there is no successful approach to chronically increase
FAO and improve whole-animal obesity-induced insu-
lin resistance in vivo.
Here we achieved hepatic gene transfer of CPT1A
(CPT1 liver isoform) to obese mice by injecting
adeno-associated viruses (AAV) into the tail vein. This
led to a nonimmunoreactive, long-term increase in
lipid oxidation. We also used a mutant but active form
of CPT1A (CPT1AM6), which is insensitive to malo-
nyl-CoA and therefore leads to a permanent increase
in the rate of FAO, independently of the glucose-
derived malonyl-CoA levels. Our results show that an
increase in hepatic FAO through AAV-mediated gene
transfer of CPT1A and CPT1AM reduced obesity-
induced hepatic steatosis, weight gain, inflammation,
diabetes, and insulin resistance in mice consuming a
high-fat diet (HFD). Furthermore, CPT1AM expres-
sion also reduced glucose and insulin levels, and liver
steatosis in genetically obese db/db mice.
Materials and Methods
Adeno-Associated Vectors. AAV vectors, serotype 1,
AAV1-AAT-GFP, AAV1-AAT-CPT1A, and AAV1-
AAT-CPT1AM were constructed to drive mouse liver
expression of green fluorescent protein (GFP),
CPT1A, and CPT1AM, respectively. Vector plasmids
carried the human albumin enhancer element and the
human 1-antitrypsin (EalbAATp) liver-specific pro-
moter described by Kramer et al.30; the cDNA
sequence of GFP, CPT1A,31 and CPT1AM6; the
woodchuck posttranscriptional regulatory element
(WPRE, Access. No. AY468-486)32; and the bovine
growth hormone polyadenosine transcription termina-
tion signal [bGH-poly(A)] (bases 2326-2533 GenBank
Access. No. M57764). The expression cassette was
flanked by two inverted terminal repeats (ITRs)
derived from AAV2. AAV1 vectors were produced in
insect cells using baculovirus.33 The vector prepara-
tions used had titers of 1  1012, 7.6  1011, and 7.5
 1011 genome copies (gc)/ml for AAV1-AAT-GFP,
AAV1-AAT-CPT1A, and AAV1-AAT-CPT1AM
respectively.
Animals. Eight-week-old male C75Bl/6J mice were
fed for 10-15 weeks with either NCD (TestDiet
D8Y2, 10% Kcal fat) or HFD (TestDiet D8Y1, 60%
Kcal fat). Two weeks after diet treatment, AAV1 vec-
tors were administered by tail vein injection in a single
dose of 7.5  1012 gc/kg of body weight. Mice were
killed 4 to 13 weeks after virus injection. Eight-week-
old male C75BL/KsJ-db/db and C75BL/KsJ-db/þ
control mice were injected with AAV1 vectors in the
tail vein at a single dose of 7.5  1012 gc/kg and
killed 17 weeks later.
Methods. Primary mouse hepatocytes were isolated
by the collagenase method33 and used to measure
FAO to CO2.
34 Isolation of mitochondria from liver
was obtained as described.35 Measurement of CPT1
activity was determined by the radiometric method.36
Glucose and pyruvate tolerance tests (2.0 g per kg
body weight) were administered by intraperitoneal
injection after an overnight fast. Histological examina-
tion was done using formalin-fixed, paraffin-embedded
tissue sections stained with hematoxylin-eosin at the
Pathology Department of the Hospital Clinic of
Barcelona.
Statistical Analysis and Other Methods. Data are
presented as mean 6 SEM. Student’s t test was used
for statistical analysis. Differences were considered sig-
nificant at P < 0.05 and complete methods are
described in the Supporting Information.
Results
AAV1-Mediated Expression of CPT1A and CPT1AM
in Mouse Liver Increases FAO. To deliver CPT1A,
CPT1AM, and GFP as a control to the mouse liver
we prepared three adeno-associated viruses: AAV1-
CPT1A, AAV1-CPT1AM, and AAV1-GFP. The ge-
nome of each virus contained the target gene under
the control of a liver-specific promoter EalbAATp (Fig.
F11A). AAVs were administrated by the tail-vein injec-
tion to C57Bl/6J mice that had been feeding for 2
weeks on either normal chow diet (NCD) or HFD.
Mice were studied throughout the dietary treatment
and killed at either 4 or 13 weeks after AVV adminis-
tration, for short- or long-term studies, respectively
(Fig. 1A). Long-term expression of the virus was
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evaluated in mice injected with AAV-GFP until they
were 33 weeks old (Supporting Fig. 1A-D). Specific
expression of CPT1A and CPT1AM in the liver was
measured by quantitative reverse-transcription poly-
merase chain reaction (qRT-PCR) (Fig. 1B). CPT1A
mRNA expression levels were 58% and 62% higher in
liver of CPT1A- and CPT1AM-expressing mice,
respectively, compared to GFP control mice. No sig-
nificant differences were seen in other tissues such as
muscle or white adipose tissue (Fig. 1B). Liver CPT1
protein and activity levels were increased in those ani-
mals injected with AAV-CPT1A and AAV-CPT1AM
Fig. 1. Increased CPT1A mRNA, protein, activity, and oleate oxidation in CPT1A- and CPT1AM-expressing mice on HFD. (A) Experiment time
course and schema of the AAV vectors: AAV-GFP; AAV-CPT1A, and AAV-CPT1AM. The cassettes contain the GFP, CPT1A, or CPT1AM transgene
driven by liver specific EalbAATp promoter. (B) CPT1A mRNA expression in liver, epididymal white adipose tissue (epi WAT), and muscle from 14-
week-old HFD-treated mice. Primers recognize both CPT1A and CPT1AM sequences. (C) Protein levels from liver mitochondria of HFD mice. (D,E)
CPT1 activity from isolated liver mitochondria of HFD-fed mice and CPT1 activity from NCD liver mitochondria enriched cell fractions incubated
with different amounts of malonyl-CoA. Data are means 6 SEM of six experiments. (F) Oleate oxidation to CO2 from primary hepatocytes iso-
lated from HFD GFP-, CPT1A-, or CPT1AM-expressing mice. Experiments were done at 4 weeks after the virus treatment. Shown are representative
experiments performed in triplicate. n ¼ 6-10. *P < 0.05. **P < 0.05 versus GFP.
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compared to control AAV-GFP in both HFD (Fig.
1C,D) and NCD (Supporting Fig.F2 2A,B). Liver pro-
tein levels increased 3.08 6 0.2- and 3.01 6 0.15-
fold in HFD CPT1A-, and CPT1AM-expressing mice,
respectively, compared to GFP control mice (Support-
ing Fig. 1E). CPT1 activity was also higher in HFD
CPT1A-, and CPT1AM-expressing mice compared to
GFP control mice (GFP: 2.51 6 0.07, CPT1A: 3.96
6 0.25, and CPT1AM: 4.53 6 0.15 nmol.mg
prot1.min1; P < 0.05) (Fig. 1D).
CPT1AM is not inhibited by malonyl-CoA in yeast,
pancreatic b-cells, muscle cells, or primary rat hepato-
cytes.6-9 We measured CPT1 activity in the presence






Fig. 2. Metabolic parameters in CPT1A- and CPT1AM-expressing mice. (A) Body weight. *P < 0.05 HFD AAV-CPT1AM versus NCD AAV-GFP,
left panel and mice receiving CPT1A, and CPT1AM remained leaner than control 3 months after AAV injection and HFD treatment, right panel.
(B) Fasting blood glucose, left panel and insulin levels, right panel. (C) Glucose tolerance test, left panel and pyruvate tolerance test, right panel.
n ¼ 6-10. *P < 0.05.
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mitochondrion-enriched fractions of GFP-, CPT1A-,
and CPT1AM-expressing mice. At physiological con-
centrations of malonyl-CoA (1 to 10 lM), CPT1AM-
expressing mice retained up to 78% of their activity,
whereas GFP- and CPT1A-expressing mice retained
only 48% (Fig. 1E). This indicates that cells expressing
CPT1AM will retain most of their CPT1 activity in-
dependently of the malonyl-CoA levels. Notably, liver
malonyl-CoA levels were similar for GFP-, CPT1A-,
and CPT1AM-expressing mice fed on either NCD or
HFD (Supporting Fig. 1F).
Next, we examined whether the increase in CPT1
messenger RNA (mRNA), protein, and activity seen in
CPT1A- and CPT1AM-expressing mice affected fatty-
acid b-oxidation. We isolated primary hepatocytes
from GFP-, CPT1A-, and CPT1AM-expressing mice
treated with NCD or HFD and measured [1-14C]ole-
ate oxidation to CO2 and acid-soluble products
(ASPs), mainly ketone bodies. In HFD-treated mice,
FAO to CO2 increased by 20.9% 6 0.8%, and
56.4% 6 4.6% in CPT1A- and CPT1AM-expressing
mice, respectively, compared to GFP control mice
(Fig. 1F). Similar results were obtained for FAO to
ASP and total FAO (the sum of oxidation to CO2 and
ASP) in HFD-treated mice (Supporting Fig. 2C,D)
and in NCD-treated mice (Supporting Fig. 2E-G).
Importantly, oxidation rates were higher in CPT1AM-
than in CPT1A-expressing mice, consistent with the
higher efficiency of CPT1AM independently of the
glucose-derived malonyl-CoA concentrations.
Long-chain fatty-acids undergoing b-oxidation yield
acetyl-CoA moieties that have two main possible fates:
(1) entry to the Krebs cycle for complete oxidation
and adenosine triphosphate (ATP) production, or (2)
conversion to ketone bodies. We hypothesized that
accelerated b-oxidation due to CPT1A expression
could reduce the surplus of acetyl-CoA groups by way
of both pathways. Liver ATP levels of CPT1A- and
CPT1AM-expressing mice were increased compared to
control GFP mice both in NCD and HFD (Table T11).
Liver protein levels of mitochondrial hydroxymethyl-
glutaryl-CoA synthase 2 (HMGS2), the rate-limiting
enzyme of hepatic ketogenesis, were increased in
CPT1A-, and CPT1AM-expressing mice compared to
control (Fig. 1C; Supporting Figs. 1E, 2A). Consistent
with this, liver and serum levels of ketone bodies such
as b-hydroxybutyryl-CoA (BHB-CoA) were higher in
CPT1A- and CPT1AM-expressing mice than in GFP
control mice both in NCD or HFD (Table 1).
CPT1A and CPT1AM Expression Protected
from Obesity-Induced Weight Gain and Insulin
Resistance. We next examined the effects of increased
b-oxidation on the obese metabolic phenotype. Mice
injected with AAV-GFP, AAV-CPT1A, or AAV-
CPT1AM were studied under HFD treatment.
Although no weight differences were seen in CPT1A-
or CPT1AM-expressing mice on NCD, CPT1AM-
expressing mice on HFD weighed significantly less
than control mice 11 weeks after AAV infection (GFP:
38.7 6 1.4 g, CPT1AM: 32.5 6 1.3 g; P < 0.04)
(Fig. 2A). Interestingly, CPT1AM-expressing mice
showed a stronger anti-obesity effect than CPT1A-
expressing mice, most likely due to the higher FAO
rate observed in the former. The differences in weight
gain were not attributable to differences in food con-
sumption because daily rates of food intake were equal
in GFP-, CPT1A-, and CPT1AM-expressing mice
(Table 1). Notably, fasting blood glucose concentra-
tions (GFP: 128.6 6 18.0, CPT1A: 87.2 6 10.7, and
CPT1AM: 82.0 6 7.1 mg/dL; P < 0.05) and insulin
Table 1. Daily Food Intake and Metabolic Variables in Serum and Liver
NCD HFD
AAV-GFP AAV-CPT1A AAV-CPT1AM AAV-GFP AAV-CPT1A AAV-CPT1AM
Daily food intake (g) 3.43 6 0.14 3.68 6 0.12 3.49 6 0.14 2.72 6 0.15* 2.91 6 0.19 2.52 6 0.13
Serum
FFA (mM) 0.94 6 0.1 1.23 6 0.08 1.24 6 0.16 1.34 6 0.08* 1.05 6 0.07† 1.11 6 0.08†
TAG (mg/dl) 82.97 6 6.90 84.31 6 3.20 78.61 6 2.70 113.79 6 10.00* 114.09 6 9.3 89.96 6 8.3† ‡
BHB (mM) 1.40 6 0.04 1.74 6 0.04† 1.82 6 0.17† 1.57 6 0.1* 1.59 6 0.06 1.90 6 0.13† ‡
Liver
BHB-CoA (nmol/g liver) 7.4 6 0.8 9.7 6 1.1 12.6 6 1.3† 6.8 6 0.9 10.2 6 1.8 14.6 6 1.7†
ATP (nmol/g liver) 6.9 6 0.5 15.4 6 1.6† 25.1 6 2.4† ‡ 7.2 6 0.8 16.8 6 1.2† 23.2 6 2.8† ‡
Daily food intake and circulating free fatty acids (FFA) and triacylglycerides (TAG) and b-hydroxybutyrate (BHB( and b-hydroxybutyrate-CoA (BHB-CoA) and ATP
from 16-week-old overnight fasted mice. Average food intake was calculated for the period between 8 to 14 weeks of age. Data are represented as mean 6
S.E.M.
*P < 0.05 AAV-GFP HFD versus NCD.
†P < 0.05 compared to AAV-GFP on the same diet.
‡P < 0.05 compared to AAV-CPT1A versus AAV-CPT1AM on the same diet.
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levels (GFP: 0.72 6 0.10, CPT1A: 0.25 6 0.02, and
CPT1AM: 0.22 6 0.02 ng/mL; P < 0.04) were lower
in both CPT1A-, and CPT1AM-expressing mice than
in control mice on HFD, and similar to the levels found
in the mice on NCD (Fig. 2B). Glucose tolerance
(measured by way of an intraperitoneal GTT; Fig. 2C,
left panel) and gluconeogenesis (measured by way of an
intraperitoneal injection of pyruvate; Fig. 2C, right
panel) were lower in both CPT1A- and CPT1AM-
expressing mice than in HFD control mice. Thus,
CPT1A and CPT1AM expression improved the obesity-
induced diabetic and insulin-resistant phenotype.
We then examined the effect of the higher FAO lev-
els in CPT1A- and CPT1AM-expressing mice on liver
steatosis. Liver TAG content of HFD CPT1A- and
CPT1AM-expressing mice was lower than that of
HFD control mice (Fig.F3 3A). Consistent with this, cir-
culating levels of free fatty acids (FFA) and TAG were
also reduced (Table 1). Although liver from HFD con-
trol mice showed severe centrilobular steatosis, those of
CPT1A-, and to a greater extent CPT1AM-expressing
mice, were clearly improved (Fig. 3B). CPT1A- and
CPT1AM-expression did not affect liver histology in
NCD mice (Fig. 3B).
AAV-CPT1A and AAV-CPT1AM-Treatment
Reverted the HFD-Induced Increase in Hepatic Glu-
coneogenesis, Inflammation, and Reactive Oxygen
Species (ROS) Levels. We next examined the mecha-
nisms by which accelerated FAO in CPT1A- and
CPT1AM-expressing mice improved obesity-induced
diabetes and insulin resistance. Four weeks after virus
injection hepatic mRNAs levels of genes involved in
gluconeogenic, lipogenic, and inflammatory pathways
were analyzed. At this short time, glucose (data not
shown) and body weight (Fig. 2A) values were already
normalized in HFD CPT1AM-expressing mice com-
pared to HFD control mice. mRNA levels of glucose-
6-phosphatase (G6Pase) and pyruvate dehydrogenase
kinase-4 (PDK4), which are involved in the gluconeo-
genic and glycolytic pathways, were increased under
HFD treatment (Fig. F44A). The increase in G6Pase and
PDK4 expression attributed to HFD was restored to
NCD values in CPT1A- and CPT1AM-expressing
mice. No changes were observed in PEPCK mRNA
levels (Supporting Fig. 3A). We next looked at lipo-
genic enzymes such as acetyl-CoA carboxylase 1
(ACC1), diacylglycerol O-acyltransferase homolog 2
(DGAT2), and the VLDL secretory enzyme microso-
mal triacylglycerol transfer protein (MTP). ACC1 and
DGAT2 expression was lower in the HFD group, but
this decrease was restored in CPT1A- and CPT1AM-
expressing mice (Fig. 4C). Similar results were seen for
other lipogenic genes such as stearoyl-Coenzyme A
desaturase 1 (SCD1) and AAC2 mRNA levels (Sup-
porting Fig. 3B,C). Correlating with de novo lipogene-
sis normalization, the HFD-increase of MTP mRNA
levels seen in GFP control mice was blunted in
CPT1A- and CPT1AM-expressing mice, in which val-
ues returned to NCD control levels (Fig. 4C). These
results indicated that the increase in liver FAO
observed in CPT1A- and CPT1AM-expressing mice
improved liver glucose and lipid metabolism.
Obesity-induced insulin resistance has been associ-
ated with chronic, low-grade inflammation in liver and
adipose tissue.2 To investigate the involvement of
inflammation in the improvement of insulin resistance
in CPT1A- and CPT1AM-expressing mice, we meas-
ured mRNA levels of several proinflammatory markers.
mRNA levels for tumor necrosis factor alpha (TNFa),






Fig. 3. Liver TAG content and liver histology in CPT1A- and CPT1AM-expressing mice. (A) Liver TAG content of 14-week-old GFP, CPT1A-, and
CPT1AM-expressing mice. (B) Liver histological sections (hematoxylin and eosin [H&E] staining) from representative 29-week-old GFP-, CPT1A-,
and CPT1AM-expressing littermates. n ¼ 6-10. *P < 0.05.
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6 ORELLANA-GAVALDÀ ET AL. HEPATOLOGY, Month 2010
and 4.86-fold, respectively, in HFD GFP control mice
versus NCD (P < 0.04) (Fig.F5 5A). Importantly, these
values were restored to NCD values in both CPT1A-
and CPT1AM-expressing mice. Similar results were
obtained for iNOS, SOCS3, and MCP-1 (Supporting
Fig. 3D). Thus, CPT1A and CPT1AM expression and
the concomitant increase in FAO reduced obesity-
induced inflammatory stress in the liver. Oxidative
stress can cause inflammation.10 Thus, we next eval-
uated the mRNA expression of the uncoupling protein
UCP2, a thermogenic protein and a marker of oxida-
tive stress,11 and ROS liver levels. Although HFD
increased liver UCP2 mRNA levels in control mice,
this increase was blunted in CPT1A- and CPT1AM-
expressing mice (Fig. 4B). These results are consistent
with liver ROS levels analyzed from GFP-, CPT1A-,
and CPT1AM-expressing mice under NCD or HFD
treatment. HFD increased ROS levels by 77.29% 6
12.33 (P < 0.05) in control mice (Fig. 5B). However,
ROS levels in CPT1A- and CPT1AM-expressing mice
were not significantly different from NCD values.
Altogether, our results indicate that the mechanisms
by which CPT1A- and CPT1AM-expressing mice
improved obesity-induced insulin resistance and diabe-
tes involve a decrease in gluconeogenesis, restoration of
fatty-acid synthesis levels, and decreased inflammatory
and ROS levels.
Systemic Effect of Liver CPT1A and CPT1AM
Expression. We examined the systemic effect of a
chronic increase in liver FAO in adipose tissue. Epi-
didymal adipose tissue weight from CPT1A- and
CPT1AM-expressing mice on HFD was reduced by
34.57% 6 7.9%, and 68.15% 6 3.9%, respectively,
compared to HFD GFP control mice (P < 0.01) (Fig.
F66A). The stronger decrease in the epididymal fat pad
from CPT1AM-expressing mice is consistent with
their higher rate of liver FAO (Fig. 1F). Concordant
with the decrease in the adipose tissue weight, leptin
serum levels from HFD CPT1A- and CPT1AM-
expressing mice were reduced 1.8- and 2.6-fold,
respectively, compared to HFD GFP control mice
(P < 0.04) (Fig. 6B).
Obese adipose tissue is characterized by enlarged
adipocytes together with an increase in mononuclear
cell infiltration.12-15 Mononuclear cell infiltration was
lower in HFD CPT1A-expressing mice, and almost
undetectable in HFD CPT1AM-expressing mice
(Fig. 6C). Consistent with this, expression of
Fig. 4. Liver gene expression. (A-C) mRNA expression in liver of 14-week-old GFP-, CPT1A-, and CPT1AM-expressing mice on NCD (open bars)
versus HFD (filled bars). n ¼ 6-10. *P < 0.05.
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proinflammatory markers such as TNFa, IL-6, and
MCP-1 was lower in epididymal fat pads from HFD
CPT1A- and CPT1AM-expressing mice than in HFD
GFP control mice (Fig. 6D-F).
The effect of an increase in hepatic FAO on insulin
signaling was evaluated in liver, adipose tissue, muscle,
and spleen. Interestingly, HFD-induced reduction of
insulin-stimulated AKT phosphorylation was improved
in CPT1A- and CPT1AM-expressing mice not only in
liver but also in epididymal adipose tissue and muscle
(Fig.F7 7A). No differences were seen in spleen. This is
consistent with the improvements in glucose and insu-
lin levels seen in these mice (Fig. 2B,C).
AAV-CPT1AM-Treatment Improved Obesity-
Induced Insulin Resistance and Diabetes in db/db
Mice. Because CPT1AM expression gave the strongest
effect in terms of FAO, we examined the effect of
AAV-CPT1AM-treatment on genetically obese mice.
AAV-GFP or AAV-CPT1AM was injected into 8-
week-old db/db and db/þ control mice and the meta-
bolic phenotype was analyzed 3 months later.
CPT1AM treatment reduced glucose by 41.2% 6
3.5% and insulin levels by 51.3% 6 4.6% in db/db
mice (Fig. 7B,C). Hepatic steatosis was reduced (Fig.
7D) but no differences were seen in epididymal adi-
pose tissue (Supporting Fig. 3F).
Discussion
It is widely accepted that pharmacological or genetic
strategies to enhance FAO may be beneficial for the
treatment of obesity and T2D. AQ2Shulman and col-
leagues1,17 showed that increasing FAO can ameliorate
insulin resistance by reducing hepatic and intramyocellu-
lar lipid levels. However, increased rates of FAO in mus-
cle have also been associated with skeletal muscle insulin
resistance18,19 due to mitochondrial overload and incom-
plete FAO.20 Furthermore, recent studies from Hoehn
et al.21 reported that an increase of FAO has little effect
on adiposity and weight gain in mice fed HFD. These
findings raise questions about whether strategies that
increase FAO per se are sufficient to reduce whole-body
adiposity in vivo, and which are the most appropriate tis-
sue and gene targets. The data presented here support
the notion that increased flux of fatty acids exclusively
into liver mitochondria by chronic overexpression of the
Fig. 5. Liver gene expression and ROS levels. (A) mRNA expression in liver of 14-week-old GFP-, CPT1A-, and CPT1AM-expressing mice on
NCD (open bars) versus HFD (filled bars). (B) Analysis and quantification of ROS from liver total extract of 14-week-old GFP-, CPT1A-, and
CPT1AM-expressing mice on NCD (open bars) and HFD (filled bars). A.U., arbitrary units. n ¼ 6-10. *P < 0.05.
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b-oxidation key enzyme, CPT1A, protects against obe-
sity-induced insulin resistance and T2D.
The beneficial effects of CPT1A and CPT1AM
gene transfer reported here were mainly the conse-
quence of three key factors. First, the use of AAV for
long-term gene expression. Recombinant AAVs are
attractive candidates for use as human gene therapy
vehicles because they may overcome the problem of
preexisting immunity22,23 against human AAV sero-
types and produce long-term expression of the target
genes. Second, the choice of the liver as a target organ,
because it plays a central role in both energy expendi-
ture and lipid/glucose homeostasis. And third, the use
of a mutant but active form of CPT1A (CPT1AM6),
which is insensitive to its physiological inhibitor, malo-
nyl-CoA. We and others have shown that expression of
CPT1AM leads to a permanent rise in the rate of
FAO, independently of the glucose-derived malonyl-
CoA levels.7-9 Overall, the use of AAV-CPT1A and
AAV-CPT1AM led to a long-term liver-selective gene
transfer that allowed us to evaluate the metabolic
impact and underlying mechanisms of increased FAO
in HFD and genetically obese mice.
HFD CPT1A- and CPT1AM-expressing mice
showed general improvement in hepatic glucose and
lipid metabolism as a consequence of increased hepatic
fatty acid flux through mitochondria. This, in turn,
prevented intracellular lipid accumulation in liver and
adipose tissue, especially in CPT1AM-expressing mice.
However, increased fatty acid flux in the absence of a
concomitant dissipation of FAO metabolites has been
associated with enhanced ROS production24 and a
consequent inflammatory state.10,25,26 Interestingly,
CPT1A- and CPT1AM-expressing mice on HFD had
normalized liver ROS levels and inflammatory state in
both liver and adipose tissue, with a significant
decrease in proinflammatory mediators such as TNFa,
IL-6, and MCP-1. These results suggest that factors
other than a chronic FAO increase per se are responsi-
ble for ROS production and inflammation. Accumula-
tion of toxic substances (DAG or ceramides),27 hy-
poxia,28 as well as adipose tissue-derived cytokines2
might participate in the induction of ROS production
and inflammation. On the other hand, the beneficial
effect of an increased FAO rate observed in HFD
CPT1A- and CPT1AM-expressing mice might also be
attributed to a concomitant enhancement of hepatic
ketone body production (present data and29).
Although to a lesser extent, increased FAO to CO2,






Fig. 6. Adipose tissue weight, circulating leptin, histology, and gene expression. (A) Epididymal white adipose tissue (Epi WAT) weight from
GFP-, CPT1A-, and CPT1AM-expressing mice after 11 weeks on HFD. (B) Circulating leptin concentrations from GFP-, CPT1A-, and CPT1AM-
expressing mice on NCD (open bars) or HFD (filled bars). (C) Histological sections from epididymal adipose tissue from a representative GFP-,
CPT1A-, and CPT1AM-expressing littermates stained with H&E. (D-F) mRNA expression in adipose tissue of 14-week-old GFP-, CPT1A-, and
CPT1AM-expressing mice on NCD (open bars) and HFD (filled bars). n ¼ 6-10. *P < 0.05. **P < 0.05 NCD AAV-GFP versus NCD AAVCPT1A
or AAV-CPT1AM.
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and CPT1AM-expressing mice. Importantly, no
changes were seen in this case in body weight, hepatic
ROS levels, or other hepatic parameters. The present
results reinforce the idea that hepatic CPT1A-, and to
a greater extent CPT1AM-treatment, is a valid in vivo
strategy to reduce obesity and improve metabolic pa-
rameters without producing undesired alterations on






Fig. 7. Improvement of insulin signaling on HFD mice and metabolic parameters in db/db mice. Injected with AAV-CPT1A or AAV-CPT1AM. (A)
Insulin signaling in liver and epididymal white adipose tissue (WAT), as indicated by western blotting of insulin-induced AKT phosphorylation
(pAKT, Ser473) and quantification of pAKT normalized by total AKT. A.U., arbitrary units. (B) Fasting blood glucose on db/db mice 3 months after
AAV injection. (C) Insulin levels on db/db mice 3 months after AAV injection. (D) Liver histological sections from representative db/db mice 3
months after injection with AAV-GFP or AAV-CPT1AM and stained with H&E. n ¼ 8-10. *P < 0.05.
J_ID: ZHE Customer A_ID: 10-1843.R1 Customer Art: ZHE24140 Date: 29-December-10 Stage: Page: 10
ID: mohanasekars I Black Lining: [ON] I Time: 14:09 I Path: N:/3b2/HEP#/Vol00000/100664/APPFile/JW-HEP#100664
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possible side effects produced by hepatic FAO induc-
tion for periods longer than those tested in this study.
Several authors have focused on treatments to
increase FAO in order to reduce hepatic steatosis, such
as liver-specific ACC suppression5 or hepatic MCD
overexpression.4 They reported a decrease in hepatic
TAG content and insulin resistance in obese animals,
which is consistent with our findings. However, the
contribution of an increase in FAO was difficult to
discern because these were short-term studies using
approaches that also targeted other metabolic func-
tions. In contrast, a direct increase in FAO through
adenovirus-mediated overexpression of CPT1A was
reported by O’Doherty and colleagues.3 The latter
study also showed a reduction in hepatic TAG levels,
although it was too short to reveal any improvement
in insulin sensitivity. Our strategy directly and chroni-
cally increased FAO in HFD-treated mice. This led to
a decrease in hepatic TAG content and circulating
FFA and a consequent improvement in insulin signal-
ing, not only in liver but also in muscle and adipose
tissue. Thus, AAV-mediated expression of CPT1A, and
to a greater extent CPT1AM, protected mice from
HFD-induced whole-animal insulin resistance without
altering any of these parameters in NCD control mice.
The lack of pathogenicity of the AAV vectors used
and the improvement in hepatic steatosis, serum glu-
cose, and insulin levels observed in the severe obesity
developed by genetically obese db/db mice are encour-
aging results with which to address new challenges
related to this gene transfer system. Further studies
will be required to elucidate long-term risks which
involve both vector and transgene. Uncertainties sur-
rounding gene transfer such as gene integration, the
effects of long latencies, and the probability of subtle
effects during long-term gene expression must be stud-
ied with care. Furthermore, additional caution is
needed regarding the feasibility of extrapolating these
data to humans, particularly in nonalcoholic fatty liver
disease, which is considered a relatively benign disease.
In summary, we report a novel and efficient gene
therapy approach to reduce body weight, liver steato-
sis, fat accumulation in adipose tissue, and obesity-
induced diabetes and insulin resistance in rodents.
This was achieved by an AAV-mediated, long-term
increase in FAO. These results point towards CPT1A
as a new potential therapeutic target against obesity-
induced disorders.
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